A guide for easy- and difficult-to-treat hypertension

被引:17
|
作者
Schmieder, Roland E. [1 ]
Volpe, Massimo [2 ,3 ]
Waeber, Bernard [4 ]
Ruilope, Luis M. [5 ,6 ]
机构
[1] Univ Hosp Erlangen, Dept Hypertens & Nephrol, Erlangen, Germany
[2] Univ Roma La Sapienza, St Andrea Hosp, Clin & Mol Med Dept, Cardiol Unit, I-00185 Rome, Italy
[3] IRCCS Neuromed, Pozzilli, Italy
[4] CHU Vaudois, Div Physiopathol Clin, CH-1011 Lausanne, Switzerland
[5] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
[6] Univ Autonoma Madrid, Dept Publ Hlth & Prevent Med, Madrid, Spain
关键词
Hypertension; Treatment algorithm; Renal denervation; RENAL SYMPATHETIC DENERVATION; FIXED-DOSE COMBINATIONS; HIGH-BLOOD-PRESSURE; DOUBLE-BLIND; HIGH-RISK; BARORECEPTOR STIMULATION; RESISTANT HYPERTENSION; OLMESARTAN MEDOXOMIL; AMLODIPINE; THERAPY;
D O I
10.1016/j.ijcard.2013.12.125
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the blood pressure (BP) of many patients can be controlled using standard combinations, treatment of hypertension frequently represents a clinical challenge to the primary care physician. This article will review best practices for managing patients with easy-and difficult-to-treat hypertension, including preferred antihypertensive combinations, optimizing adherence and persistence, recognizingwhite-coat hypertension, and intensifying therapy for treatment-resistant patients. Each physicianmust decide based on his or her own level of experience at what point a patient becomes too challenging and would benefit fromreferral to a hypertension specialist for more intensive management and to complete the exclusion of secondary forms of arterial hypertension. With intensive pharmacotherapy, many patients with difficult-to-treat hypertension can achieve BP control. If it fails, interventional strategies (e. g., renal denervation) are a valid option to get BP controlled. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [31] Innovative approaches for difficult-to-treat populations
    Holloway, F
    INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY, 1999, 45 (02) : 150 - 150
  • [32] Innovative approaches for difficult-to-treat populations
    Leonard, D
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1998, 32 (05): : 733 - 733
  • [33] Tanezumab improves difficult-to-treat OA
    Onuora, Sarah
    NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (06) : 296 - 296
  • [34] Manifestations and Management of Difficult-to-Treat Psoriasis
    Aldredge, Lakshi M.
    Higham, Robert C.
    JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2018, 10 (04) : 189 - 197
  • [35] The challenges of difficult-to-treat Acinetobacter infections
    Richards, Guy A.
    Perovic, Olga
    Brink, Adrian J.
    CLINICAL MICROBIOLOGY REVIEWS, 2024,
  • [36] Abrocitinib for difficult-to-treat atopic dermatitis
    Lorenz, Judith
    AKTUELLE DERMATOLOGIE, 2023, 49 (12) : 546 - 546
  • [37] Severe and Difficult-to-Treat Asthma in Adults
    Israel, Elliot
    Reddel, Helen K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (10): : 965 - 976
  • [38] Targeted interventions for difficult-to-treat asthma
    Chipps, Bradley E.
    Harder, Julia M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (01) : 11 - 20
  • [39] Difficult-to-treat axial spondyloarthritis patients
    Ogut, Tahir Saygin
    Erbasan, Funda
    Sahiner, Mehmet Fatih
    Nokay, Mine
    Ogut, Ayse Yoruk
    Dilbil, Melis
    Terzioglu, Mustafa Ender
    Yazisiz, Veli
    ARCHIVES OF RHEUMATOLOGY, 2024, 39 (03) : 419 - 428
  • [40] Markers of Severity in Difficult-To-Treat Asthma
    Bush, Andrew
    PEDIATRIC PULMONOLOGY, 2017, 52 : S36 - S37